High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab
复制标题
DOI：
10.1080/14397595.2017.1317320
复制
发表时间：
2018-01-01
影响因子：
2.2
通讯作者：
Ishiguro, Naoki
中科院分区：
文献类型：
--
作者：
Hattori, Yosuke;Kojima, Toshihisa;Ishiguro, Naoki
目的：本研究旨在确定血清基质金属蛋白酶-3 (MMP-3) 水平是否可以预测接受阿达木单抗 (ADA) 治疗的类风湿性关节炎 (RA) 患者的缓解。方法：受试者为连续接受 ADA 治疗 52 周的 114 名 RA 患者。基线时和开始 ADA 治疗后 4 周实现缓解的预测因素（28 点计数疾病活动评分 -CRP (DAS28-CRP)
Objective: This study aimed to determine whether serum matrix metalloproteinase-3 (MMP-3) levels can predict remission in rheumatoid arthritis (RA) patients treated with adalimumab (ADA).Methods: Subjects were 114 RA patients continuously treated with ADA for 52 weeks. Predictive factors at baseline and 4 weeks after initiation of ADA therapy for the achievement of remission (28-point count Disease Activity Score-CRP (DAS28-CRP)